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Background: Oral tranexamic acid is effective for heavy menstrual bleeding, but the thrombosis risk with this
treatment is largely not studied.
Methods: Using nationwide registries, we assessed associations between use of oral tranexamic acid and risk
of deep-vein thrombosis or pulmonary embolism and arterial thrombosis in heart or brain in a nationwide
historical prospective cohort of Danish women aged 15 to 49 years in the period 19962017. Exclusion crite-
ria included potential confounding factors such as history of thromboembolism, anticoagulation therapy,
thrombophilia, and cancer.
Findings: Among 2¢0 million women followed for 13¢8 million person-years, 3,392 venous thromboembo-
lisms and 4,198 arterial thromboses occurred. A total of 63,896 women (3¢2%) filled 146,729 prescriptions of
oral tranexamic acid during follow-up with median filled prescription per user being one of 15 g. The age-
standardised incidence rate of venous thromboembolism was 11¢8 (95% CI 4¢6 to 30¢2) per 10,000 person-
years in oral tranexamic acid use compared to 2¢5 (2¢4 to 2¢6) per 10,000 person-years in non-use. For arterial
thrombosis, the age-standardised incidence rate per 10,000 person-years was 3¢4 (1¢1 to 10¢7) among
exposed compared to 3¢0 (2¢9 to 3¢1) in non-exposed. Comparing oral tranexamic acid use with non-use, the
adjusted incidence rate ratio was 4¢0 (1¢8 to 8¢8) for venous thromboembolism and 1¢3 (0¢4 to 4¢2) for arterial
thrombosis.
Number needed to harm per five days of treatment was 78,549 women for venous thromboembolism.
Interpretation: We found use of oral tranexamic acid to be positively associated with venous thromboembo-
lism. However, number needed to harm per five days of treatment was high.
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Heavy menstrual bleeding is a high-prevalent condition affecting
the quality of life of women worldwide. Studies objectively measur-
ing menstrual blood loss have reported heavy menstrual bleeding in
nine to 14% of pre- and perimenopausal women, while studies based
on self-assessment methods report higher frequencies, ranging
between 20 and 52% [14]. The condition negatively impacts the
physical, mental, and social wellbeing of affected women and has
been associated with unemployment and absence from work,
emphasizing the importance of effective and safe treatment options
[59].Orally administrated tranexamic acid is a potent haemostatic
agent recommended both as acute and as long-term treatment of
heavy menstrual bleeding [10,11]. While the ability of oral tranexa-
mic acid to reduce menstrual blood loss is well-established, the safety
of the drug remains a concern [12]. Being an antifibrinolytic agent,
tranexamic acid inhibits the lysis of fibrin. Fibrin constitutes the main
component of both venous and arterial thromboses, which has led to
concerns about tranexamic acid being able to stabilize an initiating
thrombosis formation and thereby increase the risk of thromboem-
bolic events [13,14]. Clinical trials on the treatment effects of oral tra-
nexamic acid on heavy menstrual bleeding, most of them including
less of 100 participants, have not been sufficiently powered to study
the association with thromboembolism, and observational studies on
the topic are sparse, small, and inconclusive [12,1519].
The influence of tranexamic acid on thromboembolic risk has pri-
marily been investigated in patients suffering from other bleeding
conditions than heavy menstrual bleeding with conflicting results in
Research in context
Evidence before this study
Randomised controlled trials studying the effect of oral tra-
nexamic acid on heavy menstrual bleeding have not been suffi-
ciently powered to assess the risk of thrombosis with this
treatment.
Two observational studies have assessed the association
between oral tranexamic acid for heavy menstrual bleeding
and risk of venous thromboembolism and reported contrary
findings.
Added value of this study
This is the first nationwide cohort study on the influence of oral
tranexamic acid for heavy menstrual bleeding on the risk of
thrombosis, accounting for a wealth of possible confounding
factors.
We report a four-fold increased incidence rate of venous
thromboembolic events associated with use of oral tranexamic
acid compared to non-use. However, number needed to harm
per five days of treatment was 78,549 women. We found no
association with arterial thrombosis.
Implications of all the available evidence
Although confirming the concern of an association with venous
thromboembolic disease, we found venous thromboembolism
to be a very rare adverse event of oral tranexamic acid when
used for a short term and in generally healthy women. This
supports a majority of studies reporting a favourable safety pro-
file of the treatment of tranexamic acid for other indications.
2 A. Meaidi et al. / EClinicalMedicine 35 (2021) 100882trauma patients, no apparent risk when given for prevention of blood
loss following vaginal delivery, and an increased risk in patients with
acute gastrointestinal bleeding [2023].
Aiming to clarify the safety of tranexamic acid as a treatment
option for heavy menstrual bleeding, this pharmacoepidemiologic
study follows a nationwide cohort of women aged 15 to 49 years
with the objective of assessing the association between use of oral
tranexamic acid and the risk of venous thromboembolism and arte-
rial thrombosis.
2. Methods
2.1. Study design and population
We conducted a nationwide historical prospective cohort study
using information from the Civil Registration System, the National
Registry of Causes of Death, the National Patient Registry, the Danish
National Registry of Medicinal Product Statistics, the Danish Medical
Birth Registry, the Registry of Legally Induced Abortions, and the Pop-
ulation Education Registry [2430]. A personal identification number
given to all Danish citizens at birth or immigration was used to reli-
ably link data from these registries.
We followed women aged 15 to 49 years from January 1st, 1996,
through December 31st, 2017. Women were only included in the
cohort if they at entry did not have a history of any kind of venous or
arterial thrombosis, hypertension, diabetes, cancer, liver disease,
thrombophilia, hemophilia, thyroid disease, endometriosis, polycys-
tic ovary syndrome, hereditary angioedema, hysterectomy, bilateral
oophorectomy, blood transfusion, use of anticoagulative medication,
use of hormone therapy, use of ulipristal acetate for treatment of
uterine fibroids, and use of haemostatics other than tranexamic acid(Supplementary Appendix Table S1). Immigrated women had to have
lived in Denmark for at least one year before entry.
Women were followed until the end of the study period, the age
of 50 years, date of emigration from the country, time of death, or
time of the experience of one of the criterions of exclusion, whichever
came first.
This national cohort study was approved by the Danish Data Pro-
tection Agency and the Danish Health Data Board. Registry-based
studies are not subject to ethics approval in Denmark.
AM and CTP had access to the raw data from January 2017.
2.2. Oral tranexamic acid
If a woman filled a prescription of oral tranexamic acid, she was
considered a user. The Danish National Registry of Medicinal Product
Statistics holds information on all filled prescriptions in Denmark
since 1995 [26]. Searching the Anatomical Therapeutic Chemical
code of tranexamic acid (B02AA02) and conditioning on oral adminis-
tration, we identified users of oral tranexamic acid. In Denmark, oral
tranexamic acid cannot be purchased over-the-counter.
Oral tranexamic acid is primarily used in the acute management
of heavy menstrual bleeding. One gram three times a day in five days
is the most frequently prescribed dosage [31]. The majority of women
only fill a single prescription of 15 gs, corresponding to the standard
treatment of one menstrual bleeding [31]. Thus, most users of oral
tranexamic acid in current study are treated for five days [31].
To account for a potential delay in treatment initiation, six expo-
sure windows were assessed from the date of filled prescription; 1)
five days initiated at date of filled prescription (exposure time of five
days), 2) five days initiated sometime in the first week from date of
filled prescription (exposure window of five days plus one week), 3)
five days initiated sometime in the two weeks following date of filled
prescription (exposure window of five days plus two weeks), 4) five
days initiated sometime in the three weeks from date of filled pre-
scription (exposure window of five days plus three weeks), 5) five
days initiated sometime in the four weeks following date of filled
prescription (exposure window of five days plus four weeks), 6) five
days initiated sometime in the eight weeks following date of filled
prescription (exposure window of five days plus eight weeks),
respectively. The exposure window that provided the highest inci-
dence rate of thrombosis was considered the most reliable definition.
2.3. Thromboembolic events
A woman was considered to experience an event of interest, if she
received a diagnosis (classified according to The International Classifi-
cation of Diseases, 10th revision) of deep-vein thrombosis (I8013),
pulmonary embolism (I26), acute myocardial infarction (I21), or
thrombotic stroke (I634, except I636) in the National Patient Regis-
try or in the National Registry of Causes of Death [25,27]. Diagnoses
of deep-vein thrombosis and pulmonary embolism given only in the
emergency department have low validity and were therefore not
considered. A sensitivity analysis included only diagnoses of venous
thromboembolisms followed by a filled prescription of relevant anti-
coagulation therapy within six months from date of diagnosis. Most
women receive initial anticoagulation therapy at the hospital without
prescription, which is why a six-month window is needed to capture
prescription redemption.
2.4. Confounding factors
A woman was temporarily censored during pregnancy and for six
months after delivery and twelve weeks after other types of preg-
nancy terminations (Supplementary Appendix Table S1). The Danish
Medical Birth Registry and The Registry of Legally Induced Abortions
hold information on all births and induced abortions undergone in
A. Meaidi et al. / EClinicalMedicine 35 (2021) 100882 3Denmark since 1973, respectively, including date of birth/abortion
and gestational age at birth/abortion, allowing the calculation of esti-
mated date of conception and thereby the temporarily censoring of
women during and following pregnancy [28,29]. Similarly, miscar-
riages, extrauterine pregnancies, and pregnancies with unknown
locations diagnosed or treated in a hospital setting are registered in
the National Patient Registry with date of termination and gestational
age at that time point [27]. Miscarriages diagnosed and treated in the
primary health care sector were not detectable. The completeness of
pregnancy registrations in the Medical Birth Registry, The Registry of
Legally Induced Abortions, and in the National Patient Registry is
expected to be very high, considering that the recordings are manda-
tory and necessary for the departments to receive governmental pay-
ment for their services.
If a woman had uterine surgery (other than a hysterectomy) or
any kind of surgery demanding hospitalization for more than one
day, she was temporarily censored in eight weeks from day of dis-
charge (Supplementary Appendix Table S1). Furthermore, a woman
was also temporarily censored during use of hormonal contraception,
other systemic progestogens, or nonsteroidal antiinflammatory drugs
(Supplementary Appendix Table S1).
A woman was considered a user of hormonal contraception, if she
filled a prescription of such. In Denmark, purchase of any hormonal
contraceptive demands a prescription and is registered in the
National Registry of Medicinal Product Statistics [26]. Time exposed
to hormonal contraception was defined from date of filled prescrip-
tion. For hormonal contraceptives administrated orally, by patch,
injection, or vaginal ring, duration of use was determined by amount
of defined daily doses purchased. According to previous studies,
duration of usage of intrauterine systems and implants was assumed
to be one year less of the maximal possible usage to account for possi-
ble early discontinuation [32,33]. All exposure periods were extended
by 28 days to account for delays in initiation of use.
Due to the different possible dosages of systemic cyclic progesto-
gen-only therapy, we used the program medicinMacro, available in
the R package “github/tagteam/heaven”, to calculate the most likely
time and duration of treatment. The calculation was based on infor-
mation on time of purchase and amount purchased, provided by the
Registry of Medicinal Product Statistics, as well as information on
minimal, maximal, and default dosage, defined according to the rec-
ommendations provided in the summary of product characteristics
[26]. The program assumed the default dosage at the initiation of
treatment. If more than one purchase occurred, the program calcu-
lated whether treatment could have been continuous with minimal
dosage or maximal dosage based on data of up to five previous pur-
chases. All calculated treatment periods were extended with 28 days
to account for possible delays in treatment initiation.
Time exposed to nonsteroidal antiinflammatory drugs was
assumed to be one week from a filled prescription of any such drug.
Temporarily censored time periods did not contribute with per-
son-time or thromboembolic events in the analyses, and women
experiencing an event, death, emigration, or any exclusion criterion
during a temporarily censored time period were permanently cen-
sored from that time point.
Time-updated information on age, calendar time, and educational
level was also retrieved (Supplementary Appendix Table S1). Infor-
mation on body-mass index and smoking status was available for
parous women only as it was recorded at first visit to a midwife dur-
ing pregnancy (Supplementary Appendix Table S1).
2.5. Statistical analysis
Poisson regressions were used to estimate adjusted incidence rate
ratios with 95% confidence intervals of venous thromboembolism
and arterial thrombosis according to use of oral tranexamic acid. The
reference group was non-use in all analyses.All reported incidence rate ratios were adjusted for age and calen-
dar time in five-year intervals as well as educational level (elemen-
tary school only, secondary school only, skilled worker, theoretical
education, theoretical education with research qualifications).
Age-standardised incidence rates of venous thromboembolism
and arterial thrombosis were calculated according to use of oral tra-
nexamic acid using the age distribution of the entire cohort as the
standard. Age-standardised absolute rate differences (age-standar-
dised incidence ratesexposed - age-standardised incidence ratesunex-
posed) were then calculated. All rates were reported per 10,000
person-years. Number needed to harm per five days of treatment
was also assessed (1/[age-standardised incidence ratesexposed - age-
standardised incidence ratesunexposed].
As a supplement, number of oral tranexamic acid users and num-
ber of thromboses during use were explored among excluded and
censored women as well as among women temporarily censored.
Data were managed with SAS software, version 9.4 (SAS Institute),
while analysed using R software [34].
2.6. Role of the funding source
The research was supported by the Danish Heart Foundation,
which had no role in any part of the scientific process.
3. Results
3.1. Characteristics of the study population
A total of 1977,669 women were included in the cohort (Fig. 1)
and followed up for 13,811,917 person-years with a median (first to
third quantile) follow-up time of 5¢3 years (2¢1 to 10¢8 years). During
this period, 3392 women had a first venous thromboembolism of
which 932 (27¢5%) were coded as pulmonary embolisms, and 4198
had a first arterial thrombosis of which 1343 (32¢0%) were coded as
acute myocardial infarctions. Of all observed diagnoses of venous
thromboembolisms, 1433 diagnoses (42¢2%) were confirmed by a
filled prescription of relevant anticoagulation therapy within six
months from diagnosis.
A total of 63,896 (3¢2%) women filled at least one prescription of
oral tranexamic acid during follow-up. Characteristics of the cohort
according to use of oral tranexamic acid are shown in Table 1.
3.2. Pattern of oral tranexamic acid utilization in the study population
The 63,896 unique users of oral tranexamic acid filled a total of
146,729 prescriptions of 3064,859 gs of oral tranexamic acid during
follow-up. Of these prescriptions, around 75% accounted for 15 g, 16%
for 30 g, 1% for 45 g, 7% for 50 g, and 1% for 60 g. Pattern of oral tra-
nexamic acid use according to age at prescription redemption is illus-
trated in Table 2. Median (first to third quantile) number of filled
prescriptions per user was 1 (1 to 2), and median dose redeemed per
user was 15 g (15 to 30 g), accounting for the standard treatment of
one menstrual bleeding. The medians were similar across age. Of all
users, 33¢4% filled at least two prescriptions, and 42¢7% filled at least
30 g, accounting for the standard treatment of at least two menstrual
bleedings. Use of oral tranexamic acid peaked in women aged 45 to
49 years.
3.3. The adjusted incidence rate ratios of thrombosis associated with use
of oral tranexamic acid
During follow-up, between the date of filling a prescription of oral
tranexamic acid and up to eight weeks from that date, 26 thrombo-
embolic events were observed among the users of tranexamic acid,
16 venous thromboembolisms (eight confirmed) and ten arterial
thromboses (Table 3).
Fig. 1. Flow-diagram of the formation of the study cohort.
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peaked, when time window for exposure to oral tranexamic
acid was defined as five days plus one week from date of filled
prescription.As compared with non-use, use of oral tranexamic acid was asso-
ciated with a significant increased incidence rate ratio of venous
thromboembolism, 4¢0 (95% CI 1¢8 to 8¢8), and an incidence rate ratio
of arterial thrombosis of 1¢3 (0¢4 to 4¢2, Table 4).
Table 1
Characteristics of the study population according to use of oral tranexamic acid.
Non-use of oral
tranexamic acid
Use of oral tranexamic
acid*
No. of Person-Yr (Column Percentage)
Total 13,809,120 (100¢0) 2797 (100¢0)
Age group (years)
1519 2035,257 (14¢7) 54 (1¢9)
2024 1342,642 (9¢7) 49 (1¢8)
2529 1528,323 (11¢1) 101 (3¢6)
3034 1886,799 (13¢7) 216 (7¢7)
3539 2247,529 (16¢3) 462 (16¢5)
4044 2432,309 (17¢6) 803 (28¢7)
4549 2336,261 (16¢9) 1112 (39¢8)
Calendar time
19961999 2178,716 (15¢8) 808 (28¢9)
20002004 3288,351 (23¢8) 763 (27¢3)
20052009 3063,439 (22¢2) 612 (21¢9)
20102014 2962,300 (21¢5) 431 (15¢4)




6679,445 (48¢4) 878 (31¢4)
Secondary school only 1086,276 (7¢9) 147 (5¢3)
Skilled worker 3503,158 (25¢4) 1122 (40¢1)




616,941 (4¢5) 129 (4¢6)
Body-mass index (kg/
m2)
<18¢5 57,051 (0¢4) 11 (0¢4)
18¢525 810,750 (5¢9) 95 (3¢4)
>25 to 30 283,220 (2¢1) 51 (1¢8)
>30 162,209 (1¢2) 38 (1¢4)
Unknown 12,495,890 (90¢5) 2602 (93¢0)
Smoking status
Yes 546,774 (4¢0) 117 (4¢2)
No 2190,589 (15¢9) 399 (14¢3)
Unknown 11,071,757 (80¢2) 2281 (81¢6)
*Five days of exposure to oral tranexamic acid was assumed per 15 g redeemed¢
Exposure was assumed to occur from date of filled prescription.
Table 2
Oral tranexamic acid utilization according to age.
Age Users First-time users P
group (years) n % n % N
1519 1578 2¢2   2800
2024 1923 2¢6 1825 94¢9 2683
2529 3828 5¢3 3648 95¢3 5637
3034 7216 9¢9 6746 93¢5 12,283
3539 12,384 17¢0 11,100 89¢6 24,534
4044 19,675 27¢1 17,119 87¢0 41,771
4549 26,059 35¢9 21,880 84¢0 57,021
Total 72,663 100¢0 63,896 87¢9 146,729
*Median (first to third quantile).
Table 3
Number of observed thromboembolic events among women purchasing oral t
age at time of purchase.




# From day of filled prescription of oral tranexamic acid.
*For the remaining percentages, women were censored before the end of the e
a thromboembolic event of interest.
"Reported in the () is the number of diagnoses confirmed by a filled prescriptio
A. Meaidi et al. / EClinicalMedicine 35 (2021) 100882 5A sensitivity analysis of only confirmed venous thromboembo-
lisms did not materially change the main estimate of the association
between use of oral tranexamic acid and venous thromboembolism,
4¢3 (1¢4 to 13¢3).
In total, 329,375 parous women had information on both body-
mass index and smoking status. Of these women, 6080 filled at least
one prescription of oral tranexamic acid. No venous thromboembo-
lisms or arterial thromboses occurred in the time window of five
days plus one week following date of filled prescription among these
users. Thus, we were not able to estimate incidence rate ratios
adjusted for body-mass index and smoking status.
3.4. The age-standardised incidence rates of thrombosis associated with
use of oral tranexamic acid and numbers needed to harm
While the age-standardised incidence rate of venous thromboem-
bolism was 2¢5 (2¢4 to 2¢6) per 10,000 person-years in non-use of
oral tranexamic acid, the difference in age-standardised incidence
rate of venous thromboembolism between use and non-use was 9¢3
(8¢4 to 10¢3) per 10,000 person-years; approximately one extra
venous thromboembolism was diagnosed for every 78,549 women
using oral tranexamic acid for five days.
For arterial thrombosis, the age-standardised incidence rate in
non-use was 3¢0 (2¢9 to 3¢1) per 10,000 person-years, and the differ-
ence between use and non-use of oral tranexamic acid was non-sig-
nificant, 0¢4 (0¢7 to 1¢5) per 10,000 person-years, the best estimated
number needed to harm being 1826,262 for five days of treatment.
All exposed women experiencing a venous thromboembolism
within five days plus one week from date of filled prescription only
purchased 15 g of oral tranexamic acid prior to the event.
3.5. Thromboses in excluded and censored users of oral tranexamic acid
Only five additional thromboses occurred in excluded and perma-
nently censored users of oral tranexamic acid (Supplementary
Appendix Table S2). Similarly, only five venous thromboembolisms
were observed during concomitant use of oral tranexamic acid and
combined hormonal contraception, and even fewer thromboses wererescriptions Prescribed dose
% n per user* Gram % gram per user*
1¢9 1 (12) 59,605 1¢9 15 (1530)
1¢8 1 (11) 53,421 1¢7 15 (1515)
3¢8 1 (11) 110,168 3¢6 15 (1530)
8¢4 1 (12) 236,541 7¢7 15 (1530)
16¢7 1 (12) 506,112 16¢5 15 (1530)
28¢5 1 (12) 880,315 28¢7 15 (1545)
38¢9 1 (12) 1218,697 39¢8 15 (1545)
100¢0 1 (12) 3064,859 100¢0 15 (1530)
ranexamic acid within eight weeks from a filled prescription according to
ns Percent of prescriptions followed
eight weeks or until event*
Events within eight weeks#
Venous" Arterial
96¢2 3 (0) 0
92¢7 13 (8) 10
93¢2 16 (8) 10
ight-week period for an exclusion criterion other than the occurrence of
n of relevant anticoagulation therapy within six months from diagnosis.
Table 4
Adjusted incidence rate ratios of venous and arterial thrombosis according to use of oral tranexamic acid in women aged 1549 years.
Venous thromboembolism Arterial thrombosis
Use of oral tranexamic
acid
No. of Person-Yr No.# Age-standardised









No 13,807,520 3386 (1430) 2¢5 (2¢4 to 2¢6) Reference 4195 3¢0 (2¢9 to 3¢1) Reference
Yes 4397 6 (3) 11¢8 (4¢6 to 30¢2) 4¢0 (1¢8 to 8¢8) 3 3¢4 (1¢1 to 10¢7) 1¢3 (0¢4 to 4¢2)
# Reported in () is the number of diagnoses confirmed by a filled prescription
of relevant anticoagulation therapy within six months from diagnosis.
*Adjusted for age, calendar time, and educational level.
6 A. Meaidi et al. / EClinicalMedicine 35 (2021) 100882observed in concomitant use with systemic progestogens or nonste-
roidal antiinflammatory drugs (Supplementary Appendix Table S3).
4. Discussion
In this historical prospective cohort study, use of oral tranexamic
acid implied an increased incidence rate of venous thromboembolism
compared to non-use. However, number needed to harm per five
days of treatment was high. Use of oral tranexamic acid was not
found to be significantly associated with arterial thrombosis.
Oral tranexamic acid is one of the most effective medical therapies
for heavy menstrual bleeding [12]. Even after the appearance of the
levonorgestrel-releasing intrauterine device, oral tranexamic acid
still plays an essential role in the acute management of heavy men-
strual bleeding which no other currently available medical therapy
can fill. It also provides a possibility of treatment for women with a
current desire of pregnancy or women with contraindications against
hormonal therapy and surgical treatment not possible due to a future
desire of pregnancy.
In Denmark, oral tranexamic acid is primarily prescribed in the
acute management of heavy menstrual bleeding, while the levonor-
gestrel-releasing intrauterine system is used in the long-term man-
agement [31]. As a long-term treatment option, the levonorgestrel-
releasing intrauterine system has shown to be superior and is signifi-
cantly more affordable compared to oral tranexamic acid [12,31]. In
view of the lack of alternative medical therapies in the acute handling
of heavy menstrual bleeding, our findings, based on this pattern of
short-term use, is of high clinical relevance.
In women not exposed to oral tranexamic acid, we found the age-
standardised incidence rate of venous and arterial thrombosis to be 3
per 10,000 person-years, respectively. The incidence rates are compa-
rable with previous studies on the occurrence of thrombotic disease
in reproductive-aged women outside the time of surgery, pregnancy,
and use of hormonal contraception [32,33].
We found the age-standardised incidence rate difference of
venous thromboembolism between users and non-users of oral tra-
nexamic acid to be of the same order as the age-standardised inci-
dence rate difference between use and non-use of combined oral
contraceptives, which are used regularly to treat heavy menstrual
bleeding [10,34,35]. The age-standardised incidence rate difference
was smaller than that of combined oral contraceptives containing
desogestrel, gestodene, drospirenone, or cyproterone, but larger than
that of combined oral contraceptives including norethisterone, levo-
norgestrel, or norgestimate [33,35].
Recently, it was concluded that prior randomised controlled trials
have not been adequately powered to study the association between
oral tranexamic acid for heavy menstrual bleeding and risk of throm-
botic disease [12].
Only two observational studies have assessed the association
between use of oral tranexamic acid for heavy menstrual bleeding
and risk of venous thromboembolism [18,19]. One indicated an
increased risk, the other a protective effect [18,19]. The case-control
suggesting a protective effect (odds ratio 0.55 (0.31 to 0.97)) did notadjust for any potentially confounding factors other than age and
geography. In the same study population, use of oral contraceptives
was associated with two-fold odds of venous thromboembolism. Oral
contraceptives are also known to reduce the risk of heavy menstrual
bleeding and thereby the need for oral tranexamic acid [10,12]. Thus,
the apparent protective effect of tranexamic acid usage is likely
explained by the lack of controlling for use of oral contraceptives
[18].
This nationwide cohort study following around 2.0 million
women for a total of almost 14 million person-years adds novel
knowledge about the safety profile of a drug used to treat a high-fre-
quent condition among reproductive-aged women. Through the reli-
able national registries, we were able to include all eligible women
with no loss-to-follow-up and to eliminate a wealth of possible con-
founding factors such as use of hormonal contraception and preg-
nancy. In the Danish National Patient Registry, the positive predictive
value of a first-time diagnosis of either deep-vein thrombosis or pul-
monary embolism in a non-emergency department is quite high, i.e.
89% [36]. Since most patients receive free anticoagulation therapy
from the hospital without prescription following a venous thrombo-
embolism, we were only able to confirm 42% of diagnoses. Neverthe-
less, we found a similar incidence rate ratio after restricting to
diagnoses of venous thromboembolism followed by purchase of anti-
coagulation therapy, confirming the validity of our main findings and
a non-differential misclassification of the potential 11% false-positive
diagnoses.
We were able to exclude women with known increased risk of
thrombotic disease. These restrictions were made to investigate, if
oral tranexamic acid, in itself, and not in the presence of thrombotic
risk factors, is associated with thrombotic disease. Since the majority
of reproductive-aged women are in good health without thrombo-
genic diseases, the restrictions do not undermine the external valid-
ity of our findings, which is further confirmed by the consistency
between the observed incidence rate of thrombotic disease in the ref-
erence population in the current study and the existing literature on
reproductive-aged women [32,33].
Since the effect of oral tranexamic acid on heavy menstrual bleed-
ing is well-established in randomised trials, it would be unethical to
initiate a randomised trial for the purpose of investigating a possible
fatal adverse event in patients suffering from a non-fatal condition
that may be managed successfully with other treatment options. Con-
sidering that we had to follow more than 60,000 oral tranexamic acid
users redeeming around 150,000 prescriptions to observe 16 venous
thromboembolisms and ten arterial thromboses, a randomised trial
would have to be of a significant size in order to study the risk of
thrombosis associated with oral tranexamic acid in women with
heavy menstrual bleeding. Thus, logistically, it would be very difficult
and expensive to execute such randomised controlled trial. There-
fore, we believe a non-interventional post-authorization safety study,
such as the one conducted, to be the best possible way to study the
research question of interest.
Though the exact time of menstrual bleeding was not available,
we were able to estimate the time of oral tranexamic acid use based
A. Meaidi et al. / EClinicalMedicine 35 (2021) 100882 7on information on the exact date of prescription redemption and the
knowledge that oral tranexamic acid primarily is being used for the
acute management of heavy menstrual bleeding in Denmark [31].
However, oral tranexamic acid provided in a hospital setting was not
available. This could have led to an underestimation of the associa-
tion between use of oral tranexamic acid and risk of thrombosis, since
women given the drug at the hospital would be assumed non-users.
The potential underestimation is expected to be minor, considering
that medical treatment of heavy menstrual bleeding primarily is initi-
ated in the primary health care sector and therefore identifiable in
the Registry of Medicinal Product Statistics [26].
Although being able to create a somewhat homogenous and
healthy cohort of women, we were not able to study the association
in heavily menstruating women exclusively. This may have led to
some residual confounding by indication. Anemia may occur due to
heavy menstrual bleeding and has been linked to an increased risk of
venous thromboembolism [19]. However, by censoring at time of
blood transfusion, we were able to exclude women with severe ane-
mia.
We were not able to adjust for body-mass index and smoking sta-
tus. The summary of product characteristics of oral tranexamic acid
states a precaution of use in women with thrombogenic risk factors
such as increased body-mass index and smoking. Thus, if anything,
the lack of adjustment would tend to underestimate the association,
since more non-users would be obese or smokers.
Finally, adjustment for body-mass index, smoking, and anemia
(defined as a serum hemoglobin value of < 11.5 g/dl) was done in the
previously mentioned case-control study, which only included men-
orrhagia patients, and which reported an, although non-significant,
increased risk of venous thromboembolism associated with oral tra-
nexamic acid usage, indicating an association independent of the fac-
tors missing in current study [19].
Despite the above-mentioned limitations, the study clearly dem-
onstrates that in a population of healthy women, venous thrombo-
embolism and arterial thrombosis are maximally very rare adverse
events of temporarily, short-lasting use of oral tranexamic acid,
which is comparable with the risk attached to use of combined oral
contraception.
Further study is warranted to determine the association between
use of oral tranexamic acid and risk of thrombosis in women with
known risk factors for venous thromboembolism and arterial throm-
bosis and in prolonged use of oral tranexamic acid.Declaration of Competing Interest
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